Bellus Health

Pipeline

Clinical Trials

The Phase 2 RELIEF (A Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough) trial is a dose escalation, placebo-controlled, and crossover design to assess the efficacy, safety, and tolerability of BLU-5937 in patients with refractory chronic cough. Approximately 65 patients are expected to be enrolled at 12 clinical sites in the United Kingdom and United States. The RELIEF trial was initiated in July 2019 and top-line results are anticipated in mid-2020.

clinicaltrials.gov

Approximately 65 patients with refractory unexplained chronic cough are expected to be enrolled at 12 clinical sites in the United Kingdom and United States